This has partially been achieved for the treatment of CTCL, where antibody‐dependent cell cytotoxicity against CCR4 depletes malignant CD4+ TRM and results in long‐lasting cancer control in some individuals.235. Here, CCR4 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.